Evidence map›Paper›PMID 34752469›Full record

ArticlePLoS genetics2021

The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma.

Irena Bočkaj, Tosca E I Martini, Eduardo S de Camargo Magalhães, Petra L Bakker, Tiny G J Meeuwsen-de Boer, Inna Armandari, Saskia L Meuleman, Marin T Mondria, Colin Stok, Yannick P Kok and 12 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Epigenomic insights into common human disease pathology.Cellular and molecular life sciences : CMLS · 2024
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 4 countries.

Irena BočkajDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0001-5824-2414
Tosca E I MartiniDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0002-6534-0685
Eduardo S de Camargo MagalhãesDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0002-7726-4827
Petra L BakkerDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Tiny G J Meeuwsen-de BoerDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Inna ArmandariDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0003-0551-6666
Saskia L MeulemanDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0002-0240-0513
Marin T MondriaDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0002-6473-6418
Colin StokDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0003-4736-5130
Yannick P KokDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0001-7041-5496
Bjorn BakkerDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0003-3095-7287
René WardenaarDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0001-9891-1897
Jonas SeilerDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0002-0993-8834
Mathilde J C BroekhuisDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0003-2064-8528
Hilda van den BosDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0001-9787-8597
Diana C J SpieringsDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Femke C A RingnaldaPrincess Máxima Center for Pediatric Oncology, Oncode Institute, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0002-0684-4613
Hans CleversPrincess Máxima Center for Pediatric Oncology, Oncode Institute, University Medical Center Utrecht, Utrecht, the Netherlands.
Ulrich SchüllerResearch Institute Children's Cancer Center Hamburg, Hamburg, Germany.ORCID 0000-0002-8731-1121
Marcel A T M van VugtDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Floris FoijerDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Sophia W M BruggemanDepartment of Ageing Biology/ERIBA, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0002-2678-323X
University Medical Center Groningen · NLRoyal Netherlands Academy of Arts and Sciences · NLUniversidade Federal do Rio de Janeiro · BRUniversität Hamburg · DEUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While comprehensive molecular profiling of histone H3.3 mutant pediatric high-grade glioma has revealed extensive dysregulation of the chromatin landscape, the exact mechanisms driving tumor formation remain poorly understood. Since H3.3 mutant gliomas also exhibit high levels of copy number alterations, we set out to address if the H3.3K27M oncohistone leads to destabilization of the genome. Hereto, we established a cell culture model allowing inducible H3.3K27M expression and observed an increase in mitotic abnormalities. We also found enhanced interaction of DNA replication factors with H3.3K27M during mitosis, indicating replication defects. Further functional analyses revealed increased genomic instability upon replication stress, as represented by mitotic bulky and ultrafine DNA bridges. This co-occurred with suboptimal 53BP1 nuclear body formation after mitosis in vitro, and in human glioma. Finally, we observed a decrease in ultrafine DNA bridges following deletion of the K27M mutant H3F3A allele in primary high-grade glioma cells. Together, our data uncover a role for H3.3 in DNA replication under stress conditions that is altered by the K27M mutation, promoting genomic instability and potentially glioma development.

Indexed as

Genomic InstabilityBrain NeoplasmsChildDNA ReplicationGene Expression Regulation, NeoplasticGliomaHistonesHumansMitosisHistones

Identifiers

PMID34752469
PMCPMC8604337
OpenAlexW3212664292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.